@article{8a0f003d7d074f74aa32fe560386d4e9,
title = "Machine learning in the prediction of depression treatment outcomes: A systematic review and meta-analysis",
abstract = "Background: Multiple treatments are effective for major depressive disorder (MDD), but the outcomes of each treatment vary broadly among individuals. Accurate prediction of outcomes is needed to help select a treatment that is likely to work for a given person. We aim to examine the performance of machine learning methods in delivering replicable predictions of treatment outcomes. Methods: Of 7732 non-duplicate records identified through literature search, we retained 59 eligible reports and extracted data on sample, treatment, predictors, machine learning method, and treatment outcome prediction. A minimum sample size of 100 and an adequate validation method were used to identify adequate-quality studies. The effects of study features on prediction accuracy were tested with mixed-effects models. Fifty-four of the studies provided accuracy estimates or other estimates that allowed calculation of balanced accuracy of predicting outcomes of treatment. Results: Eight adequate-quality studies reported a mean accuracy of 0.63 [95% confidence interval (CI) 0.56-0.71], which was significantly lower than a mean accuracy of 0.75 (95% CI 0.72-0.78) in the other 46 studies. Among the adequate-quality studies, accuracies were higher when predicting treatment resistance (0.69) and lower when predicting remission (0.60) or response (0.56). The choice of machine learning method, feature selection, and the ratio of features to individuals were not associated with reported accuracy. Conclusions: The negative relationship between study quality and prediction accuracy, combined with a lack of independent replication, invites caution when evaluating the potential of machine learning applications for personalizing the treatment of depression.",
keywords = "MDD, Machine learning, meta-analysis, predictive analysis, systematic review, treatment outcome",
author = "Mehri Sajjadian and Lam, {Raymond W.} and Roumen Milev and Susan Rotzinger and Frey, {Benicio N.} and Soares, {Claudio N.} and Parikh, {Sagar V.} and Foster, {Jane A.} and Gustavo Turecki and M{\"u}ller, {Daniel J.} and Strother, {Stephen C.} and Faranak Farzan and Kennedy, {Sidney H.} and Rudolf Uher",
note = "Funding Information: Drs. Sajjadian, Foster, Turecki, Farzan, and Uher report no conflict of interest. Dr Lam has received honoraria or research funds from Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, CIHR, CANMAT, Canadian Psychiatric Association, Hansoh, Healthy Minds Canada, Janssen, Lundbeck, Lundbeck Institute, MITACS, Ontario Brain Institute, Otsuka, Pfizer, St. Jude Medical, University Health Network Foundation, and VGH-UBCH Foundation. Dr Milev has received honoraria or research funds from Ontario Brain Institute, Allergan, Janssen, Lallemand, Kye, Lundbeck, Nubiyota, Otsuka, Pfizer, and Sunovion. Dr Rotzinger holds a patent {\textquoteleft}Teneurin C-Terminal Associated Peptides (TCAP) and methods and uses thereof. Inventors: David Lovejoy, R.B. Chewpoy, Dalia Barsyte, Susan Rotzinger.{\textquoteright} Dr Frey had a research grant from Pfizer. Dr M{\"u}ller is funded by a CIHR operating grant 428404. Dr Soares has acted as a consultant for Servier, Sunovion, Lundbeck, and Otsuka. Dr Parikh has received honoraria or research funds from Assurex, Takeda, Janssen, Mensante, Aifred, Sage. Dr Strother is the Chief Scientific Officer of ADMdx, Inc., which receives NIH funding. Dr Kennedy has received honoraria or research funds from Abbott, Alkermes, Allergan, BMS, Brain Canada, CIHR, Janssen, Lundbeck, Lundbeck Institute, Ontario Brain Institute, Ontario Research Fund, Otsuka, Pfizer, Servier, Sunovion, Xian-Janssen, and Field Trip Health. Funding Information: This work has been funded by the Ontario Brain Institute, which is an independent non-profit corporation, funded partially by the Ontario Government. The opinions, results, and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding was provided by the Canadian Institutes of Health Research (CIHR), Lundbeck, Bristol-Myers Squibb, and Servier. Funding and/or in-kind support was also provided by the investigators' universities and academic institutions. Dr Uher has received additional support from the Canada Research Chairs Program (award number 231397), the Canadian Institutes of Health Research (Grant reference number 148394), and the Dalhousie Medical Research Foundation. Funding Information: This work was conducted as part of the Canadian Biomarker Integration Network in Depression (CAN-BIND), an Integrated Discovery Program, supported by the Ontario Brain Institute. Publisher Copyright: Copyright {\textcopyright} 2021 The Author(s). Published by Cambridge University Press.",
year = "2021",
month = dec,
day = "12",
doi = "10.1017/S0033291721003871",
language = "English (US)",
volume = "51",
pages = "2742--2751",
journal = "Psychological Medicine",
issn = "0033-2917",
publisher = "Cambridge University Press",
number = "16",
}